1. Home
  2. KC vs REPL Comparison

KC vs REPL Comparison

Compare KC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kingsoft Cloud Holdings Limited

KC

Kingsoft Cloud Holdings Limited

SELL

Current Price

$6.36

Market Cap

2.4B

Sector

Technology

ML Signal

SELL

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

SELL

Current Price

$20.17

Market Cap

2.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KC
REPL
Founded
2012
2015
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
KC
REPL
Price
$6.36
$20.17
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$20.27
★ $25.50
AVG Volume (30 Days)
1.2M
★ 3.2M
Earning Date
11-24-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.76
N/A
Revenue Next Year
$27.68
$449.28
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.85
$1.50
52 Week High
$18.52
$23.64

Technical Indicators

Market Signals
Indicator
KC
REPL
Relative Strength Index (RSI) 26.90 61.39
Support Level N/A $7.19
Resistance Level $9.22 N/A
Average True Range (ATR) 0.37 1.46
MACD -0.13 0.07
Stochastic Oscillator 3.86 54.87

Price Performance

Historical Comparison
KC
REPL

About KC Kingsoft Cloud Holdings Limited

Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: